+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Meningococcal Vaccines Market Report 2024-2034

  • PDF Icon

    Report

  • 239 Pages
  • March 2024
  • Region: Global
  • Visiongain
  • ID: 5806053
Overall world revenue for Meningococcal Vaccines Market, 2024 to 2034 in terms of value the market will surpass US$3,100.0 million in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Meningococcal Vaccines Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Difficulties in R&D

Introduction of vaccine requires immense amount of research and development. Key factors that impact R&D include lack of infrastructure, limited funding opportunities, barriers to obtaining raw material, operational insufficiencies. Furthermore, R&D costs can be manageable for large dominant players while small players face various. challenges. Also, regulatory processes are complex and require lot of documentation and follow-up that further adds to time consuming process for vaccine research. Hence, there is a need to streamline R&D process for enhancing research.

Key Questions Answered

  • How is the Meningococcal Vaccines market evolving?
  • What is driving and restraining the Meningococcal Vaccines market?
  • How will each Meningococcal Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each Meningococcal Vaccines submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading Meningococcal Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Meningococcal Vaccines projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of Meningococcal
  • Vaccines projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Meningococcal Vaccines market?
  • Where is the Meningococcal Vaccines market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Meningococcal Vaccines market today, and over the next 10 years:

  • This 239-page report provides 105 tables, 161 charts and graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Meningococcal Vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Meningococcal Vaccines prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type

  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Combination Vaccines
  • Men B Vaccines

Serogroups

  • A, B, C, Y, W-135 Vaccines
  • Serogroup B Vaccines

Brands

  • Menactra
  • Menveo
  • Nimenrix
  • Bexsero
  • Trumenba

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

  • BIO-MED
  • GSK plc
  • Hualan Biological Bacterin Co., Ltd.
  • Incepta Pharmaceuticals Ltd.
  • JN International
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Walvax Biotechnology Co., Ltd.

How will the Meningococcal Vaccines Market, 2024 to 2034 report help you?

In summary, the 230+ page report provides you with the following knowledge:
  • Revenue forecasts to 2034 for Meningococcal Vaccines Market, 2024 to 2034 Market, with forecasts for type, serogroups, brands, and distribution channel each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Meningococcal Vaccines Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Meningococcal Vaccines Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Meningococcal Vaccines Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Meningococcal Vaccines Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Meningococcal Vaccines Market Size Estimation and Forecast by Type
4.4 Polysaccharide vaccines
4.4.1 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.4.2 Polysaccharide vaccines Market Share by Region, 2024-2034 (%)
4.5 Conjugate vaccines
4.5.1 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.5.2 Conjugate vaccines Market Share by Region, 2024-2034 (%)
4.6 Combination vaccines
4.6.1 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.6.2 Combination Vaccines Market Share by Region, 2024-2034 (%)
4.7 Men B vaccines
4.7.1 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
4.7.2 Men B vaccines Market Share by Region, 2024-2034 (%)
5 Meningococcal Vaccines Market Analysis by Serogroups
5.1 Key Findings
5.2 Serogroups Segment: Market Attractiveness Index
5.3 Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
5.4 Meningococcal Vaccines Market Share by Serogroups, 2024 & 2034
5.5 A, B, C, Y, W-135 vaccines
5.5.1 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
5.5.2 A, B, C, Y, W-135 vaccines Market Share by Region, 2024-2034 (%)
5.6 Serogroup B vaccines
5.6.1 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
5.6.2 Serogroup Men B Vaccines Market Share by Region, 2024-2034 (%)
6 Meningococcal Vaccines Market Analysis by Brand
6.1 Key Findings
6.2 Menactra
6.2.1 Menactra Market Forecast, 2024-2034 (US$ Mn)
6.3 Menveo
6.3.1 Menveo Market Forecast, 2024-2034 (US$ Mn)
6.4 Nimenrix
6.4.1 Nimenrix Market Forecast, 2024-2034 (US$ Mn)
6.5 Bexsero
6.5.1 Bexsero Market Forecast, 2024-2034 (US$ Mn)
6.6 Trumenba
6.6.1 Trumenba Market Forecast, 2024-2034 (US$ Mn)
7 Meningococcal Vaccines Market Analysis by Distribution Channel
7.1 Key Findings
7.2 Distribution Channel Segment: Market Attractiveness Index
7.3 Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
7.4 Meningococcal Vaccines Market Share by Distribution Channel, 2024, 2029, 2034
7.5 Hospital Pharmacies
7.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
7.6 Retail Pharmacies
7.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
7.7 Online Pharmacies
7.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
7.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)
8 Meningococcal Vaccines Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
9 North America Meningococcal Vaccines Market Analysis
9.1 Key Findings
9.2 North America Meningococcal Vaccines Market Attractiveness Index
9.3 North America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
9.4 North America Meningococcal Vaccines Market Size Estimation and Forecast by Country
9.5 North America Meningococcal Vaccines Market Size Estimation and Forecast by Type
9.6 North America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
9.7 North America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
9.8 U.S.
9.8.1 U.S. Meningococcal Vaccines Market by Type
9.9 Canada
9.9.1 Canada Meningococcal Vaccines Market by Type
10 Europe Meningococcal Vaccines Market Analysis
10.1 Key Findings
10.2 Europe Meningococcal Vaccines Market Attractiveness Index
10.3 Europe Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
10.4 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Country
10.5 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Type
10.6 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
10.7 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
10.8 Germany
10.8.1 Germany Meningococcal Vaccines Market by Type
10.9 U.K.
10.9.1 U.K. Meningococcal Vaccines Market by Type
10.10 France
10.10.1 France Meningococcal Vaccines Market by Type
10.11 Italy
10.11.1 Italy Meningococcal Vaccines Market by Type
10.12 Spain
10.12.1 Spain Meningococcal Vaccines Market by Type
10.13 Rest of Europe
10.13.1 Rest of Europe Meningococcal Vaccines Market by Type
11 Asia Pacific Meningococcal Vaccines Market Analysis
11.1 Key Findings
11.2 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
11.3 Asia Pacific Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
11.4 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Country
11.5 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Type
11.6 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
11.7 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
11.8 Japan
11.9 China
11.9.1 China Meningococcal Vaccines Market by Type
11.10 India
11.10.1 India Meningococcal Vaccines Market by Type
11.11 South Korea
11.11.1 South Korea Meningococcal Vaccines Market by Type
11.12 Australia
11.12.1 Australia Meningococcal Vaccines Market by Type
11.13 Rest of APAC
11.13.1 Rest of APAC Meningococcal Vaccines Market by Type
12 Latin America Meningococcal Vaccines Market Analysis
12.1 Key Findings
12.2 Latin America Meningococcal Vaccines Market Attractiveness Index
12.3 Latin America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
12.4 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Country
12.5 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Type
12.6 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
12.7 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
12.8 Brazil
12.8.1 Brazil Meningococcal Vaccines Market by Type
12.9 Mexico
12.10 Rest of Latin America
12.10.1 Rest of LATAM Meningococcal Vaccines Market by Type
13 MEA Meningococcal Vaccines Market Analysis
13.1 Key Findings
13.2 MEA Meningococcal Vaccines Market Attractiveness Index
13.3 MEA Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
13.4 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Country
13.5 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Type
13.6 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
13.7 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
13.8 South Africa
13.8.1 South Africa Meningococcal Vaccines Market by Type
13.9 GCC
13.9.1 GCC Meningococcal Vaccines Market by Type
13.10 Rest of MEA
13.10.1 Rest of MEA Meningococcal Vaccines Market by Type
14 Competitive Landscape
14.1 Company Market Share Analysis
14.2 Key Business Strategy Analysis
15 Company Profiles
15.1 GSK plc
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.4 Product Benchmarking
15.1.5 Pipeline Analysis
15.1.6 Strategic Outlook
15.2 BIO-MED
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.3 Hualan Biological Bacterin Co., Ltd.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Product Benchmarking
15.4 Incepta Pharmaceuticals Ltd.
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.5 JN International
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Product Benchmarking
15.6 Pfizer Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Sanofi
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.4 Product Benchmarking
15.7.5 Pipeline Analysis
15.7.6 Strategic Outlook
15.8 Serum Institute of India Pvt. Ltd
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.8.4 Strategic Outlook
15.9 Walvax Biotechnology Co., Ltd.
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Pipeline Analysis
16 Conclusion and Recommendations
16.1 Concluding Remarks
16.2 Recommendations for Market Players

Companies Mentioned

  • BIO-MED
  • GSK plc
  • Hualan Biological Bacterin Co., Ltd.
  • Incepta Pharmaceuticals Ltd.
  • JN International
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Biovac
  • EuBiologics
  • Novartis
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious. Diseases (NIAID) [U.S.]
  • National Institutes of Health [U.S.]
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Administration (FDA) [U.S.]
  • Health Canada
  • National Development and Reform Commission (NDRC) [China]
  • National Health Services (NHS) [UK]
  • National Pharmaceutical Pricing Authority (NPPA) [China]
  • Pan American Health Organization (PAHO)
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • World Health Organization (WHO)